You can take Celebrex (celecoxib) if you have G6PD deficiency
Celecoxib is not contraindicated in G6PD deficiency and can be used safely with standard precautions. There is no evidence linking COX-2 selective inhibitors like celecoxib to hemolytic anemia in G6PD-deficient patients.
Evidence-Based Classification
The most comprehensive and recent guideline on G6PD deficiency and medications 1 systematically reviewed all drugs previously implicated as unsafe in G6PD deficiency. Only seven medications have solid evidence for prohibition: dapsone, methylthioninium chloride (methylene blue), nitrofurantoin, phenazopyridine, primaquine, rasburicase, and tolonium chloride 2. Celecoxib is notably absent from this list.
NSAIDs and G6PD Deficiency: The Real Story
While some NSAIDs have been reported to cause immune hemolytic anemia through autoimmune or immune complex mechanisms 3, this is:
- Extremely rare (occurring in the general population, not specifically G6PD-deficient patients)
- Not related to G6PD deficiency itself - the mechanism is immunologic, not oxidative stress
- Most commonly associated with mefenamic acid, not celecoxib
A comprehensive review found that NSAIDs do not significantly increase hemolysis risk in G6PD-deficient individuals 3. The confusion arose because many drugs were wrongly cited as causing hemolysis when they were simply administered during infection-related hemolytic episodes 2.
Real-World Safety Data
A large real-world study of 31,962 G6PD-deficient patients found only 71 cases (0.2%) of major hemolysis requiring hospitalization over 13 years 4. Of these:
- 71.8% were caused by fava beans
- 8.5% by infections
- Only 4.2% possibly medication-related (nitrofurantoin, phenazopyridine, and one unspecified "pain killer")
No cases were attributed to celecoxib or other COX-2 inhibitors.
Important Caveats About Celebrex
While celecoxib is safe regarding G6PD deficiency, you should still be aware of its standard risks 5, 6:
- Cardiovascular risk: Increased risk of MI, stroke, and thrombotic events (especially with prolonged use or cardiovascular risk factors)
- Gastrointestinal risk: Ulceration, bleeding, and perforation
- Renal complications: Can cause volume-dependent renal failure
- Blood pressure elevation: Average increase of 5 mm Hg
These risks apply to all patients, not specifically those with G6PD deficiency.
Bottom Line
Celecoxib can be prescribed to G6PD-deficient patients using the same precautions as for any other patient 1, 2. The decision to use or avoid celecoxib should be based on standard cardiovascular, gastrointestinal, and renal risk factors—not G6PD status.